Lothian NHS Board

Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG



Telephone: 0131 536 9000 www.nhslothian.scot.nhs.uk

Date: 29/02/2024 Our Ref: 8395

Enquiries to loth.freedomofinfomation@nhs.scot

Dear

FREEDOM OF INFORMATION - MIGRAINE TREATMENT

I write in response to your request for information in relation to migraine treatment in NHS Lothian.

Question:

1. How many patients have been treated with the following drugs in the past 4 months: Atogepant (Aquipta) – any disease; Erenumab (Aimovig) - any disease; Eptinezumab (Vyepti) – any disease; Fremanezumab (Ajovy) - any disease; Galcanezumab (Emgality) - any disease; Rimegepant (Vydura) – any disease; Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY?

Answer:

The information you have requested is detailed in the table below:

Number of patients treated, October 2023 to January 2024, NHS Lothian,	
Medication	Number of patients
Atogepant	0
Eptinezumab	0
Erenumab	96
Fremanezumab	33
Galcanezumab	12
Rimegepant	0
Botulinum Toxin (for migraine only)	184

Question:

2. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs: Atogepant; Erenumab; Eptinezumab; Fremanezumab; Galcanezumab; Rimegepant; Botulinum Toxin?

Answer:

The information for these specific diagnoses is not held centrally. Information may be held in individual patient records, but in order to provide the information you request it would be necessary to review each patient record over the period you have specified, requiring significant resources. Under section 12 of the Freedom of Information (Scotland) Act 2002,









Headquarters Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG



NHS Lothian is not required to respond to your request if the resources required to do so equate to more than £600 in cost.

Question:

3. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Answer:

Yes, a treatment pause is initiated within 2 years of the patient being on CRRPs.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI

Yours sincerely

ALISON MACDONALD Executive Director of Nursing Midwifery and AHPs

Cc: Chief Executive